There is a dearth of systematic data on efficacy and safety of ibutilide in children and adults with CHD and also in pediatric age-group patients. To determine the efficacy and safety of ibutilide in these populations, and to characterize the determinants of its efficacy. Patients with CHD and children < 18 years old with structurally normal hearts were recruited between Jan 1, 2010 and Dec 1, 2020. Logistic regression models were used to determine the effect of covariates on odds of successful cardioversion with ibutilide. 53 patients underwent 105 chemical cardioversions (age: 27.5 ± 10.4 years [75% males], 80% atrial flutter) with ibutilide during the study period. The overall rate of successful cardioversion with ibutilide in our cohort was 70.4% (mean ibutilide dose: 1.5 ± 0.65 mg). Presentation in atrial flutter (P = 0.08) and male gender (0.07) showed a trend towards significance. Adverse effects were reported after 8 ibutilide administrations (7.6%, n = 6/8 [75%] female).
Keywords: Adult congenital heart disease; Chemical cardioversion; Children; Ibutilide; Ventricular tachycardia.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.